Advanced Science,
Год журнала:
2024,
Номер
unknown
Опубликована: Ноя. 25, 2024
Abstract
Lipid
Nanoparticles
(LNPs)
recently
emerged
as
an
invaluable
RNA
delivery
platform.
With
many
LNP‐based
therapeutics
in
the
pre‐clinical
and
clinical
pipelines,
there
is
extensive
research
dedicated
to
improving
LNPs.
These
efforts
focus
mainly
on
tolerability
transfectability
of
new
ionizable
lipids
RNAs,
or
modulating
LNPs
biodistribution
with
active
targeting
strategies.
However,
most
formulations
follow
well‐established
lipid
proportions
used
clinically
approved
products.
Nevertheless,
investigating
effects
composition
their
can
expand
toolbox
for
particle
design,
leading
improved
Herein,
a
(30‐n‐LNPs)
formulation
increasing
amounts
phospholipids
investigated
possible
mRNA
system
treating
Inflammatory
Bowel
Diseases.
Compared
benchmark
(b‐LNPs),
n‐LNPs
containing
30%
distearoylphosphatidylcholine
(DSPC)
are
well
tolerated
following
intravenous
administration
display
natural
toward
inflamed
colon
dextran
sodium
sulfate
(DSS)‐colitis
bearing
mice,
while
de‐targeting
clearing
organs
such
liver
spleen.
Using
interleukin‐10‐encoding
therapeutic
cargo,
demonstrated
reduction
pathological
burden
colitis‐bearing
mice.
represent
starting
point
further
investigate
influence
systemic
biodistribution,
ultimately
opening
modalities
different
pathologies.
Journal of Biomedical Science,
Год журнала:
2024,
Номер
31(1)
Опубликована: Сен. 10, 2024
Abstract
Realizing
the
immense
clinical
potential
of
mRNA-based
drugs
will
require
continued
development
methods
to
safely
deliver
bioactive
agents
with
high
efficiency
and
without
triggering
side
effects.
In
this
regard,
lipid
nanoparticles
have
been
successfully
utilized
improve
mRNA
delivery
protect
cargo
from
extracellular
degradation.
Encapsulation
in
was
an
essential
factor
successful
application
vaccines,
which
conclusively
demonstrated
technology's
yield
approved
medicines.
review,
we
begin
by
describing
current
advances
modifications,
design
novel
lipids
nanoparticle
components
for
drugs.
Then,
summarize
key
points
pertaining
preclinical
therapeutics.
Finally,
cover
topics
related
targeted
systems,
including
endosomal
escape
targeting
immune
cells,
tumors
organs
use
vaccines
new
treatment
modalities
human
diseases.
Journal of Experimental & Clinical Cancer Research,
Год журнала:
2024,
Номер
43(1)
Опубликована: Ноя. 29, 2024
Abstract
AKT,
or
protein
kinase
B,
is
a
central
node
of
the
PI3K
signaling
pathway
that
pivotal
for
range
normal
cellular
physiologies
also
underlie
several
pathological
conditions,
including
inflammatory
and
autoimmune
diseases,
overgrowth
syndromes,
neoplastic
transformation.
These
pathologies,
notably
cancer,
arise
if
either
activity
AKT
its
positive
negative
upstream
downstream
regulators
effectors
goes
unchecked,
superimposed
on
by
intersection
with
slew
other
pathways.
Targeting
PI3K/AKT
is,
therefore,
prudent
countermeasure.
inhibitors
have
been
tested
in
many
clinical
trials,
primarily
combination
drugs.
While
some
recently
garnered
attention
their
favorable
profile,
concern
over
resistance
off-target
effects
continued
to
hinder
widespread
adoption
clinic,
mandating
discussion
alternative
modes
targeting.
In
this
review,
we
discuss
isoform-centric
targeting
may
be
more
effective
less
toxic
than
traditional
pan-AKT
significance
disease
prevention
treatment,
immunotherapy.
We
touch
emerging
mutant-
allele-selective
covalent
allosteric
(CAAIs),
as
well
indirect,
novel
AKT-targeting
approaches,
end
briefing
ongoing
quest
reliable
biomarkers
predicting
sensitivity
response
inhibitors,
current
state
affairs.
ACS Applied Bio Materials,
Год журнала:
2024,
Номер
7(8), С. 5020 - 5036
Опубликована: Янв. 30, 2024
In
medicine,
it
is
desirable
for
clinicians
to
be
able
restore
function
and
imbue
novel
into
selected
cells
therapy
disease
prevention.
Cells
damaged
by
disease,
injury,
or
aging
could
programmed
normal
lost
functions,
such
as
retinal
in
inherited
blindness
neuronal
Alzheimer's
disease.
also
genetically
with
functions
immune
expressing
synthetic
chimeric
antigen
receptors
immunotherapy.
Furthermore,
knockdown
modification
of
risk
factor
proteins
can
mitigate
development.
Currently,
nucleic
acids
are
emerging
a
versatile
potent
therapeutic
modality
achieving
this
cellular
programming.
review,
we
highlight
the
latest
developments
nanobiomaterials-based
acid
therapeutics
programming
from
biomaterial
design
delivery
perspective
how
overcome
barriers
their
clinical
translation
benefit
patients.
Asian Journal of Pharmaceutical Sciences,
Год журнала:
2025,
Номер
20(1), С. 101015 - 101015
Опубликована: Янв. 5, 2025
The
recent
commercialization
of
gene
products
has
sparked
significant
interest
in
therapy,
necessitating
efficient
and
precise
delivery
via
various
vectors.
Currently,
viral
vectors
lipid-based
nanocarriers
are
the
predominant
choices
have
been
extensively
investigated
reviewed.
Beyond
these
vectors,
polymeric
also
hold
promise
therapeutic
owing
to
their
versatile
functionalities,
such
as
improving
stability,
cellar
uptake
endosomal
escape
nucleic
acid
drugs,
along
with
targeted
tissues.
This
review
presents
a
brief
overview
status
quo
emerging
for
delivery,
focusing
on
key
cationic
polymers,
nanocarrier
types,
preparation
methods.
It
highlights
diseases,
strategies
improve
efficiency,
potential
future
directions
this
research
area.
is
hoped
inspire
development,
optimization,
clinical
translation
highly
delivery.
Frontiers in Bioengineering and Biotechnology,
Год журнала:
2025,
Номер
12
Опубликована: Янв. 15, 2025
Gene
therapy
has
emerged
as
a
pivotal
component
in
the
treatment
of
diverse
genetic
and
acquired
human
diseases.
However,
effective
gene
delivery
remains
formidable
challenge
to
overcome.
The
presence
degrading
enzymes,
acidic
pH
conditions,
gastrointestinal
mucus
layer
pose
significant
barriers
for
therapy,
necessitating
exploration
alternative
therapeutic
options.
In
recent
years,
transdermal
transpulmonary
modalities
offer
promising
avenues
with
multiple
advantages,
such
non-invasion,
avoided
liver
first-pass
effect
improved
patient
compliance.
Considering
rapid
development
therapeutics
via
administration,
here
we
aim
summarize
nearest
advances
drug
delivery.
this
review,
firstly
elaborate
on
current
carrier
therapy.
We,
further,
describe
approaches
applications
enhancing
encompassing
microneedles,
chemical
enhancers,
physical
methods
administration
well
nebulized
formulations,
dry
powder
pressurized
metered
dose
formulations
efficient
Last
but
not
least,
opportunities
outlooks
through
both
administrated
routes
are
highlighted.
